

Rami A Al-Horani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1986430/publications.pdf>

Version: 2024-02-01

42
papers

1,170
citations

361413
20
h-index

395702
33
g-index

46
all docs

46
docs citations

46
times ranked

1308
citing authors

#	ARTICLE	IF	CITATIONS
1	Factor IX(a) inhibitors: an updated patent review (2003-present). Expert Opinion on Therapeutic Patents, 2022, 32, 381-400.	5.0	7
2	Sulfonated non-saccharide molecules and human factor Xla: Enzyme inhibition and computational studies. Chemical Biology and Drug Design, 2022, 100, 64-79.	3.2	6
3	Ethacrynic acid is an inhibitor of human factor XIIIa. BMC Pharmacology & Toxicology, 2022, 23, .	2.4	0
4	Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19. Cardiovascular Drugs and Therapy, 2021, 35, 195-203.	2.6	39
5	Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients. Current Pharmaceutical Design, 2021, 27, 866-875.	1.9	20
6	Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase. ACS Omega, 2021, 6, 12699-12710.	3.5	13
7	Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor Xla. Pharmaceuticals, 2021, 14, 886.	3.8	8
8	Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present). Expert Opinion on Therapeutic Patents, 2020, 30, 39-55.	5.0	35
9	Studies on fragment-based design of allosteric inhibitors of human factor Xla. Bioorganic and Medicinal Chemistry, 2020, 28, 115762.	3.0	6
10	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 5224.	4.1	42
11	Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. American Journal of Cardiovascular Drugs, 2020, 20, 525-533.	2.2	23
12	Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia. ChemistryOpen, 2020, 9, 1161-1172.	1.9	12
13	Targeting factor XI(a) for anticoagulation therapy: a patent landscape. Pharmaceutical Patent Analyst, 2020, 9, 3-5.	1.1	9
14	Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism. European Journal of Medicinal Chemistry, 2020, 200, 112442.	5.5	18
15	Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies. Current Medicinal Chemistry, 2020, 27, 3412-3447.	2.4	12
16	Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. Viruses, 2020, 12, 1092.	3.3	34
17	A synthetic heparin mimetic that allosterically inhibits factor Xla and reduces thrombosis in vivo without enhanced risk of bleeding. Journal of Thrombosis and Haemostasis, 2019, 17, 2110-2122.	3.8	22
18	New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations. International Journal of Molecular Sciences, 2019, 20, 3013.	4.1	14

#	ARTICLE	IF	CITATIONS
19	The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis. <i>Molecules</i> , 2019, 24, 2146.	3.8	12
20	A small group of sulfated benzofurans induces steady-state submaximal inhibition of thrombin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1101-1105.	2.2	17
21	Recent advances in the discovery and development of factor XI/XIa inhibitors. <i>Medicinal Research Reviews</i> , 2018, 38, 1974-2023.	10.5	56
22	Inhibition of Herpes Simplex Virus-1 Entry into Human Cells by Nonsaccharide Glycosaminoglycan Mimetics. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 797-802.	2.8	27
23	Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 641-657.	6.4	28
24	Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 15, 40-48.	1.0	13
25	Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile. <i>PLoS ONE</i> , 2016, 11, e0160189.	2.5	18
26	Allosteric Partial Inhibition of Monomeric Proteases. Sulfated Coumarins Induce Regulation, not just Inhibition, of Thrombin. <i>Scientific Reports</i> , 2016, 6, 24043.	3.3	32
27	Factor XIa inhibitors: A review of the patent literature. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 323-345.	5.0	58
28	Plasmin Regulation through Allosteric, Sulfated, Small Molecules. <i>Molecules</i> , 2015, 20, 608-624.	3.8	22
29	Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 379-387.	1.7	38
30	Glycosaminoglycan-Protein Interaction Studies Using Fluorescence Spectroscopy. <i>Methods in Molecular Biology</i> , 2015, 1229, 335-353.	0.9	12
31	Synthesis of Glycosaminoglycan Mimetics Through Sulfation of Polyphenols. <i>Methods in Molecular Biology</i> , 2015, 1229, 49-67.	0.9	11
32	Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 12, 91-125.	1.0	20
33	Recent Advances on Plasmin Inhibitors for the Treatment of Fibrinolysis-Related Disorders. <i>Medicinal Research Reviews</i> , 2014, 34, 1168-1216.	10.5	65
34	Synthetic, Non-saccharide, Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells. <i>ACS Chemical Biology</i> , 2014, 9, 1826-1833.	3.4	37
35	Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4805-4818.	6.4	49
36	395 Synthetic, Non-Saccharide Glycosaminoglycan Mimetics Selectively Target Colon Cancer Stem Cells. <i>Gastroenterology</i> , 2014, 146, S-84-S-85.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Sulfated Pentagalloylglucoside Is a Potent, Allosteric, and Selective Inhibitor of Factor Xla. Journal of Medicinal Chemistry, 2013, 56, 867-878.	6.4	81
38	Discovery of Allosteric Modulators of Factor Xla by Targeting Hydrophobic Domains Adjacent to Its Heparin-Binding Site. Journal of Medicinal Chemistry, 2013, 56, 2415-2428.	6.4	38
39	Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold. European Journal of Medicinal Chemistry, 2012, 54, 771-783.	5.5	19
40	Electronically rich N-substituted tetrahydroisoquinoline 3-carboxylic acid esters:Âconcise synthesis and conformational studies. Tetrahedron, 2012, 68, 2027-2040.	1.9	19
41	Designing Nonsaccharide, Allosteric Activators of Antithrombin for Accelerated Inhibition of Factor Xa. Journal of Medicinal Chemistry, 2011, 54, 6125-6138.	6.4	33
42	Chemical sulfation of small moleculesâ€”advances and challenges. Tetrahedron, 2010, 66, 2907-2918.	1.9	145